Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FLHSO
ADC Name
Docetaxel-trastuzumab
Synonyms
Docetaxel trastuzumab
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Docetaxel
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 60
%
SK-BR-3 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 60.00% (Day 67) Positive HER2 expression (HER2 +++/++)
Method Description
Docetaxel and trastuzumab (5 and 1.9 mg/kg, respectively,every seven days 3) induces efficient tumor cell killing in cell line-derived models of SKBR3 cells with HER2 expression with high expression.
In Vivo Model SKBR-3 CDX model
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.